Author

C. T. Jordan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

B. M. Stevens· 4 shared A. E. Gillen· 3 shared A. Krug· 2 shared A. Winters· 2 shared D. A. Pollyea· 2 shared H. Tolison· 2 shared J. DeGregori· 2 shared K. Engel· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

B. M. Stevens

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium

A. I. Sheth, K. Engel, H. Tolison, M. J. Althoff, M. L. Amaya, A. Krug, T. Young, S. Pei, S. B. Patel, M. Minhajuddin, A. Winters, R. Miller, I. Shelton, J. St-Germain, T. Ling, , C. T. Jordan

This study identifies mitochondrial calcium utilization as a metabolic requirement of venetoclax-resistant acute myeloid leukemia stem cells and shows that targeting mitochondrial calcium uptake can eradicate these cells.

bioRxiv · Oct 2, 2023Cancer Biology

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy

S. Pei, A. E. Gillen, I. T. Shelton, B. M. Stevens, M. Gasparetto, K. Engel, S. Staggs, Y. Wang, W. Showers, A. Inguva, M. L. Amaya, M. Minhajuddin, A. Winters, S. B. Patel, H. Tolison, , C. T. Jordan

The paper identifies a new type of monocytic leukemia stem cell (m-LSC) in AML patients treated with venetoclax, showing its distinct characteristics and clinical relevance.

Cancer Discovery · Sep 6, 2023Peer-reviewedCancer Biology

MuVEH and mitoMuVEH improve discovery of genetic variation from single cells.

M. R. Ransom, K. L. Engel, B. M. Stevens, C. T. Jordan, A. E. Gillen

MuVEH and mitoMuVEH enhance variant detection in scRNA-seq and enable clonal relationship reconstruction in AML patients.

bioRxiv · Nov 22, 2022 · PreprintCancer Biology

Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation

H. J. Park, M. A. Gregory, V. Zaberezhnyy, A. Goodspeed, C. T. Jordan, J. S. Kieft, J. DeGregori

The paper shows that marrow-mediated activation of ATM and mTOR increases oxidative phosphorylation, leading to resistance in FLT3 mutant AML cells, and that combining mTOR and FLT3 inhibitors reduces tumor burden.

bioRxiv · Feb 14, 2022Cancer Biology

Transcription factor PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress

J. S. Chavez, J. L. Rabe, D. Loeffler, K. Higa, G. Hernandez, T. S. Mills, N. Ahmed, R. L. Gessner, Z. Ke, B. M. Idler, H. M. Kim, J. R. Myers, B. M. Stevens, C. T. Jordan, H. Nakajima, , E. M. Pietras

This study shows that PU.1 enforces HSC quiescence by repressing protein synthesis and cell cycle genes, preventing clonal expansion during inflammatory stress.

Journal of Experimental Medicine · Apr 15, 2021Peer-reviewedImmunology